Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: ( pitches OR (switched OR (switch OR (sswitched OR unswitched))) )
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
Showing
1
-
20
of
24
Search:
'( pitches OR (switched OR (switch OR (sswitched OR unswitched))) )'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Biologic
switching
for patients with rheumatoid arthritis : a review of clinical effectiveness, safety, and guidelines
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
... and safety, as well as evidence-based clinical guidelines, on the practice of
switching
biologics, both...
”
Read Now
2
Biologic
switching
for patients with rheumatoid arthritis : a review of clinical effectiveness, safety, and guidelines
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
... and safety, as well as evidence-based clinical guidelines, on the practice of
switching
biologics, both...
”
Read Now
3
Switching
from innovator to biosimilar (subsequent entry) infliximab : an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...The potential cost savings of
switching
to biosimilars without compromising on clinical...
”
Read Now
4
Switching
from innovator to biosimilar (subsequent entry) Infliximab : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2015
CADTH Rapid Response Service
“
...
Switching
from Innovator to biosimilar Infliximab...
”
Read Now
5
Switching
from innovator to biosimilar (subsequent entry) Infliximab : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2015
CADTH Rapid Response Service
“
...
Switching
from Innovator to biosimilar Infliximab...
”
Read Now
6
Switching
from innovator to biosimilar (subsequent entry) infliximab : an updated review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...The potential cost savings of
switching
to biosimilars without compromising on clinical...
”
Read Now
7
Switching
botulinum toxin A products for patients with upper limb spasticity or cervical dystonia : a review of clinical effectiveness
by
Pohar, Ron
,
Rabb, Danielle
Published 2018
CADTH
“
... clear that the products are not interchangeable. However,
switching
may be necessary for patients who...
”
Read Now
8
Switching
botulinum toxin A products for patients with upper limb spasticity or cervical dystonia : a review of clinical effectiveness
by
Pohar, Ron
,
Rabb, Danielle
Published 2018
CADTH
“
... clear that the products are not interchangeable. However,
switching
may be necessary for patients who...
”
Read Now
9
Attention-deficit/hyperactivity disorder medication
switching
for patients with aggression or mood...
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...ADHD medication
switching
...
”
Read Now
10
Attention-deficit/hyperactivity disorder medication
switching
for patients with aggression or mood...
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...ADHD medication
switching
...
”
Read Now
11
Clinical and economic review report: Infliximab SC (Remsima) : Celltrion Healthcare Co., Ltd. : indication : rheumatoid arthritis
Published 2021
Canadian Agency for Drugs and Technologies in Health
“
... receiving infliximab IV maintenance therapy and are suitable to be
switched
to the SC formulation...
”
Read Now
12
Second-line therapy for patients with relapsing-remitting multiple sclerosis : a review of guidelines
by
Li, Ke Xin
,
Picheca, Lory
Published 2019
CADTH
“
...There is uncertainty in clinical practice regarding how and when to
switch
from the first-line...
”
Read Now
13
Second-line therapy for patients with relapsing-remitting multiple sclerosis : a review of guidelines
by
Li, Ke Xin
,
Picheca, Lory
Published 2019
CADTH
“
...There is uncertainty in clinical practice regarding how and when to
switch
from the first-line...
”
Read Now
14
Brivaracetam (Brivlera)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... is reduced in order to prevent seizures or status epilepticus during the
switch
period. Brivaracetam...
”
Read Now
15
Brivaracetam (Brivlera)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... is reduced in order to prevent seizures or status epilepticus during the
switch
period. Brivaracetam...
”
Read Now
16
Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
..., and ziprasidone; an open-label study of patients
switched
to lurasidone from another antipsychotic...
”
Read Now
17
Lurasidone hydrochloride (Latuda) : management of manifestations of schizophrenia
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
..., and ziprasidone; an open-label study of patients
switched
to lurasidone from another antipsychotic...
”
Read Now
18
Pharmacoeconomic review report: Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and sym...
Published 2020
CADTH
“
... discontinuation due to adverse events (AEs) followed by a treatment
switch
, and death...
”
Read Now
19
Ustekinumab (Stelara)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... inadequately respond to the 90 mg SC every 12 weeks regimen may be
switched
to the every eight weeks regimen....
”
Read Now
20
Ustekinumab (Stelara)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
... inadequately respond to the 90 mg SC every 12 weeks regimen may be
switched
to the every eight weeks regimen....
”
1
2
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Year of Publication
From:
To:
Classification
610 - Medicine & health
16
330 - Economics
9
700 - The arts; fine & decorative arts
3
140 - Specific philosophical schools
2
Language
English
24
Collection
National Center for Biotechnology Information
24
Author
Canadian Agency for Drugs and Technologies in Health
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
6
Li, Ke Xin
2
Picheca, Lory
2
Pohar, Ron
2
Rabb, Danielle
2
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&lookfor=%28+pitches+OR+%28switched+OR+%28switch+OR+%28sswitched+OR+unswitched%29%29%29+%29&type=AllFields
Send by Email
×
Loading...